Sang­amo/Pfiz­er are catch­ing up to Bio­Marin and Spark with a gene ther­a­py for he­mo­phil­ia A — can they leapfrog ahead?

Sang­amo re­searchers and their part­ners at Pfiz­er may be play­ing catch-up with Bio­Marin and Spark/Roche in de­vel­op­ing a gene ther­a­py to cure he­mo­phil­ia A, but they’re off to an en­cour­ag­ing start.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER